- Home
- PLRX vs QSI Comparison
PLRX vs QSI Comparison
Compare PLRX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- QSI
- Stock Information
- Founded
- PLRX 2015
- QSI 2013
- Country
- PLRX United States
- QSI United States
- Employees
- PLRX N/A
- QSI N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- QSI Health Care
- Exchange
- PLRX Nasdaq
- QSI Nasdaq
- Market Cap
- PLRX 641.5M
- QSI 633.2M
- IPO Year
- PLRX 2020
- QSI N/A
- Fundamental
- Price
- PLRX $11.77
- QSI $1.93
- Analyst Decision
- PLRX Strong Buy
- QSI Buy
- Analyst Count
- PLRX 7
- QSI 2
- Target Price
- PLRX $40.50
- QSI $3.25
- AVG Volume (30 Days)
- PLRX 544.4K
- QSI 56.4M
- Earning Date
- PLRX 02-26-2025
- QSI 02-27-2025
- Dividend Yield
- PLRX N/A
- QSI N/A
- EPS Growth
- PLRX N/A
- QSI N/A
- EPS
- PLRX N/A
- QSI N/A
- Revenue
- PLRX N/A
- QSI $2,266,000.00
- Revenue This Year
- PLRX N/A
- QSI $193.90
- Revenue Next Year
- PLRX N/A
- QSI $173.18
- P/E Ratio
- PLRX N/A
- QSI N/A
- Revenue Growth
- PLRX N/A
- QSI 232.26
- 52 Week Low
- PLRX $10.22
- QSI $0.61
- 52 Week High
- PLRX $18.92
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- PLRX 34.86
- QSI 46.00
- Support Level
- PLRX $12.40
- QSI $2.30
- Resistance Level
- PLRX $13.71
- QSI $5.77
- Average True Range (ATR)
- PLRX 0.76
- QSI 0.83
- MACD
- PLRX -0.17
- QSI -0.08
- Stochastic Oscillator
- PLRX 18.66
- QSI 15.97
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.